• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
0.95% $19.91

NEUREN PHARMACEUTICALS LIMITED - Corporate Spotlight

Market Cap $2.540B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

No Corporate Spotlight currently available.

(20min delay)
Last
$19.91 		Change
-0.190(0.95%) 		Mkt cap ! $2.540B
Open High Low Value Volume
$20.17 $20.17 $19.66 $1.467M 73.76K

Buyers (Bids)

No. Vol. Price($)
1 25 $19.90
 

Sellers (Offers)

Price($) Vol. No.
$19.93 150 3
View Market Depth
Last trade - 11.59am 03/07/2024 (20 minute delay) ?
Last
$19.93 		  Change
-0.190 ( 0.85 %)
Open High Low Volume
$20.14 $20.17 $19.66 28174
Last updated 12.18pm 03/07/2024 ?
NEU (ASX) Chart

Top Stories

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Uranium was one bright spot at the start of 2024, standing out against otherwise glum markets that defined 2023.
Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project  The company has locked in a drilling contractor to fire up a Reverse Circulation (RC) drill rig at Maverick starting on 8th of July US time. 
Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring Sun Silver executive director Gerard O'Donovan discusses a 6,216 grams Fort Intercept at the Maverick Spring Silver Project from historical data and drill assessments.
Amplia enrols new patients to progress testing for pancreatic cancer drug Amplia Therapeutics Ltd has enrolled a new group of patients to test the efficacy of its drug narmafotinib in treatment of pancreatic cancer.
Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4 Ark Mines has published an Exploration Target for its Sandy Mitchell REE project of up to 1.5B tonnes @ up to 1490ppm monazite equivalent
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.